Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High – Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $47.47 and last traded at $47.47, with a volume of 28606 shares trading hands. The stock had previously closed at $43.58.

Analysts Set New Price Targets

A number of research firms have issued reports on MAZE. Guggenheim reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Friday, December 19th. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, January 25th. Finally, HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $44.50.

Maze Therapeutics Stock Performance

The business has a 50-day moving average of $41.05 and a 200-day moving average of $29.37. The stock has a market capitalization of $2.26 billion and a price-to-earnings ratio of -2.24.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Amy Bachrodt sold 10,000 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. This represents a 43.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 180,000 shares of company stock worth $7,334,292 in the last quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the 4th quarter worth $39,000. Ameritas Investment Partners Inc. increased its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the 3rd quarter valued at about $52,000. Finally, CWM LLC acquired a new stake in Maze Therapeutics during the second quarter worth approximately $28,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.